Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis

NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD

45.38  -4.98 (-9.89%)

After market: 45.5 +0.12 (+0.26%)

Fundamental Rating

5

PTCT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. PTCT has only an average score on both its financial health and profitability. PTCT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year PTCT was profitable.
In the past year PTCT had a positive cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of 22.40%, PTCT belongs to the best of the industry, outperforming 98.00% of the companies in the same industry.
The Return On Invested Capital of PTCT (33.50%) is better than 99.27% of its industry peers.
Industry RankSector Rank
ROA 22.4%
ROE N/A
ROIC 33.5%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin of PTCT (33.55%) is better than 97.28% of its industry peers.
PTCT has a better Operating Margin (49.27%) than 99.64% of its industry peers.
With an excellent Gross Margin value of 96.87%, PTCT belongs to the best of the industry, outperforming 96.91% of the companies in the same industry.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
Industry RankSector Rank
OM 49.27%
PM (TTM) 33.55%
GM 96.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
Compared to 1 year ago, PTCT has more shares outstanding
Compared to 5 years ago, PTCT has more shares outstanding
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 1.82 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.82, PTCT is doing good in the industry, outperforming 70.05% of the companies in the same industry.
The Debt to FCF ratio of PTCT is 3.47, which is a good value as it means it would take PTCT, 3.47 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.47, PTCT belongs to the best of the industry, outperforming 93.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.47
Altman-Z 1.82
ROIC/WACC4.32
WACC7.76%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

PTCT has a Current Ratio of 3.89. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.89, PTCT is in line with its industry, outperforming 45.55% of the companies in the same industry.
PTCT has a Quick Ratio of 3.85. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PTCT (3.85) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.85
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 226.85% over the past year.
Looking at the last year, PTCT shows a very negative growth in Revenue. The Revenue has decreased by -13.97% in the last year.
PTCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.32% yearly.
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)-13.97%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%

3.2 Future

The Earnings Per Share is expected to grow by 21.94% on average over the next years. This is a very strong growth
PTCT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.69% yearly.
EPS Next Y215.08%
EPS Next 2Y24.87%
EPS Next 3Y22.96%
EPS Next 5Y21.94%
Revenue Next Year114.77%
Revenue Next 2Y3.33%
Revenue Next 3Y11.68%
Revenue Next 5Y11.69%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.00, the valuation of PTCT can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 97.10% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. PTCT is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 8
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaply inside the industry as 98.91% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaper than 98.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.19
EV/EBITDA 3.8
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PTCT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 22.96% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y24.87%
EPS Next 3Y22.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PTC THERAPEUTICS INC

NASDAQ:PTCT (8/8/2025, 8:01:45 PM)

After market: 45.5 +0.12 (+0.26%)

45.38

-4.98 (-9.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners102.55%
Inst Owner Change1.14%
Ins Owners0.63%
Ins Owner Change0.46%
Market Cap3.60B
Analysts78.26
Price Target68.2 (50.29%)
Short Float %7.47%
Short Ratio5.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2260.84%
Min EPS beat(2)-221.32%
Max EPS beat(2)4742.99%
EPS beat(4)2
Avg EPS beat(4)1127.12%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)3
Avg EPS beat(8)526.16%
EPS beat(12)3
Avg EPS beat(12)339.46%
EPS beat(16)4
Avg EPS beat(16)251.33%
Revenue beat(2)1
Avg Revenue beat(2)287.62%
Min Revenue beat(2)-10.09%
Max Revenue beat(2)585.33%
Revenue beat(4)2
Avg Revenue beat(4)146.44%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.22%
Revenue beat(12)7
Avg Revenue beat(12)50.19%
Revenue beat(16)10
Avg Revenue beat(16)39.08%
PT rev (1m)6.93%
PT rev (3m)6.99%
EPS NQ rev (1m)-0.38%
EPS NQ rev (3m)6.45%
EPS NY rev (1m)0%
EPS NY rev (3m)321.64%
Revenue NQ rev (1m)-0.94%
Revenue NQ rev (3m)3.85%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)142.06%
Valuation
Industry RankSector Rank
PE 8
Fwd PE N/A
P/S 2.03
P/FCF 5.19
P/OCF 5.2
P/B N/A
P/tB N/A
EV/EBITDA 3.8
EPS(TTM)5.67
EY12.49%
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)8.74
FCFY19.27%
OCF(TTM)8.73
OCFY19.23%
SpS22.37
BVpS-2.34
TBVpS-4.88
PEG (NY)0.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.4%
ROE N/A
ROCE 42.4%
ROIC 33.5%
ROICexc 2102.85%
ROICexgc N/A
OM 49.27%
PM (TTM) 33.55%
GM 96.87%
FCFM 39.09%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.47
Debt/EBITDA 2.39
Cap/Depr 4.95%
Cap/Sales 0.08%
Interest Coverage 202.52
Cash Conversion 76.77%
Profit Quality 116.5%
Current Ratio 3.89
Quick Ratio 3.85
Altman-Z 1.82
F-Score8
WACC7.76%
ROIC/WACC4.32
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y215.08%
EPS Next 2Y24.87%
EPS Next 3Y22.96%
EPS Next 5Y21.94%
Revenue 1Y (TTM)-13.97%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
Revenue Next Year114.77%
Revenue Next 2Y3.33%
Revenue Next 3Y11.68%
Revenue Next 5Y11.69%
EBIT growth 1Y684.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year722.81%
EBIT Next 3Y67.86%
EBIT Next 5YN/A
FCF growth 1Y315.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y339.54%
OCF growth 3YN/A
OCF growth 5YN/A